scholarly journals Plasma Biomarkers in Alzheimer’s Disease

10.5772/64512 ◽  
2016 ◽  
Author(s):  
Hitoshi Sohma ◽  
Yasuo Kokai
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Plasma Biomarkers

O3-02-05: Proteomic identification of plasma biomarkers for hippocampal atrophy in Alzheimer's disease

2008 ◽  
Vol 4 ◽  
pp. T161-T161
Author(s):  
Madhav Thambisetty ◽  
Andrew Simmons ◽  
Abdul Hye ◽  
Darragh O'Brien ◽  
James Campbell ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Hippocampal Atrophy ◽  
Plasma Biomarkers ◽  
Proteomic Identification

Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease

2018 ◽  
Vol 15 (10) ◽  
pp. 938-950 ◽  
Author(s):  
Martina Zverova ◽  
Eva Kitzlerova ◽  
Zdenek Fisar ◽  
Roman Jirak ◽  
Jana Hroudova ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Mechanisms ◽  
Neurodegenerative Disorder ◽  
Apoe Genotype ◽  
Plasma Biomarkers ◽  
Plasma Melatonin ◽  
Apoe Ε4 ◽  
Ε4 Allele ◽  
Severity Of Dementia

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis and a common occurrence of comorbid diseases such as depression. It is accepted that the presence of the ε4 allele of the gene that encodes apolipoprotein E (APOE) is the strongest genetic risk factor for the development of sporadic AD. Melatonin, cortisol, homocysteine, and prolactin are presumed to be risk factors or biomarkers for stress- and age-related disorders. Objective: The interplay between the APOE genotype and plasma biomarkers was examined in patients with AD presenting with or without depression to contribute to understanding the interdependence of various molecular mechanisms in the pathophysiology of AD. Method: The APOE genotype and morning plasma melatonin, cortisol, homocysteine, and prolactin concentrations were measured in 85 patients with AD and 44 elderly controls. Results: A significant association between AD and the allele (ε4) or genotype (ε3/ε4 or ε4/ε4) frequencies of APOE was confirmed. Plasma homocysteine and cortisol levels were significantly increased in patients with AD compared to those in controls, independent of the presence of comorbid depressive symptoms or the severity of dementia. Significantly lower plasma melatonin concentration was found in patients with AD but not in controls, who were noncarriers of the APOE ε4 allele, regardless of the presence of depression or the severity of dementia in AD. Conclusion: Our findings indicate the existence of a little-known specific APOE-mediated mechanism that increases the plasma melatonin level in a subgroup of patients with AD who are carriers of the APOE ε4 allele.

Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease

2021 ◽  
Author(s):  
Pratishtha Chatterjee ◽  
Steve Pedrini ◽  
Nicholas J. Ashton ◽  
Michelle Tegg ◽  
Kathryn Goozee ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Preclinical Alzheimer’S Disease ◽  
Plasma Biomarkers

scholarly journals Plasma Biomarkers: Potent Screeners of Alzheimer’s Disease

2019 ◽  
Vol 34 (5) ◽  
pp. 290-301 ◽  
Author(s):  
Muhammad Naveed ◽  
Shamsa Mubeen ◽  
Abeer Khan ◽  
Sehrish Ibrahim ◽  
Bisma Meer
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Plasma Proteins ◽  
Great Accuracy ◽  
Vital Role ◽  
Brain Cell ◽  
Plasma Biomarkers ◽  
Factors Associated ◽  
Specificity And Sensitivity ◽  
Complex Chronic Disease

Alzheimer’s disease (AD), a neurological disorder, is as a complex chronic disease of brain cell death that usher to cognitive decline and loss of memory. Its prevalence differs according to risk factors associated with it and necropsy performs vital role in its definite diagnosis. The stages of AD vary from preclinical to severe that proceeds to death of patient with no availability of treatment. Biomarker may be a biochemical change that can be recognized by different emerging technologies such as proteomics and metabolomics. Plasma biomarkers, 5-protein classifiers, are readily being used for the diagnosis of AD and can also predict its progression with a great accuracy, specificity, and sensitivity. In this review, upregulation or downregulation of few plasma proteins in patients with AD has also been discussed, when juxtaposed with control, and thus serves as potent biomarker in the diagnosis of AD.

scholarly journals Sleep deprivation and plasma biomarkers for Alzheimer's disease

2019 ◽  
Vol 57 ◽  
pp. 92-93 ◽  
Author(s):  
Martin Olsson ◽  
Johan Ärlig ◽  
Jan Hedner ◽  
Kaj Blennow ◽  
Henrik Zetterberg
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sleep Deprivation ◽  
Plasma Biomarkers

scholarly journals Prognostic Polypeptide Blood Plasma Biomarkers of Alzheimer's Disease Progression

2014 ◽  
Vol 40 (3) ◽  
pp. 659-666 ◽  
Author(s):  
Hongqian Yang ◽  
Yaroslav Lyutvinskiy ◽  
Sanna-Kaisa Herukka ◽  
Hilkka Soininen ◽  
Dorothea Rutishauser ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Blood Plasma ◽  
Disease Progression ◽  
Plasma Biomarkers

scholarly journals Plasma Biomarkers of Alzheimer’s Disease in African Americans

2021 ◽  
Vol 79 (1) ◽  
pp. 323-334
Author(s):  
Kaancan Deniz ◽  
Charlotte C.G. Ho ◽  
Kimberly G. Malphrus ◽  
Joseph S. Reddy ◽  
Thuy Nguyen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
African Americans ◽  
Plasma Proteins ◽  
Plasma Concentrations ◽  
Disease Status ◽  
Lower Plasma ◽  
Plasma Biomarkers ◽  
Pairwise Correlations ◽  
Inflammatory Proteins

Background/Objective: The aim of this study was to determine if plasma concentrations of 5 surrogate markers of Alzheimer’s disease (AD) pathology and neuroinflammation are associated with disease status in African Americans. Methods: We evaluated 321 African Americans (159 AD, 162 controls) from the Florida Consortium for African-American Alzheimer’s Disease Studies (FCA3DS). Five plasma proteins reflecting AD neuropathology or inflammation (Aβ42, tau, IL6, IL10, TNFα) were tested for associations with AD, age, sex, APOE and MAPT genotypes, and for pairwise correlations. Results: Plasma tau levels were higher in AD when adjusted for biological and technical covariates. APOE ɛ4 was associated with lower plasma Aβ42 and tau levels. Older age was associated with higher plasma Aβ42, tau, and TNFα. Females had lower IL10 levels. Inflammatory proteins had strong pairwise correlations amongst themselves and with Aβ42. Conclusion: We identified effects of demographic and genetic variants on five potential plasma biomarkers in African Americans. Plasma inflammatory biomarkers and Aβ42 may reflect correlated pathologies and elevated plasma tau may be a biomarker of AD in this population.

Sign in / Sign up

Export Citation Format

Share Document